Communiqués Denali Therapeutics Inc.

Actions

DNLI

US24823R1059

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 28/08/2026			Varia. 5j.	Varia. 1 janv.
24,00 ^USD	-2,72 %		-3,69 %	+45,37 %

25/08	Denali Therapeutics Inc. : B. Riley toujours positif	ZM
24/08	La FDA suspend les essais cliniques de la thérapie génique de Regenxbio contre le syndrome de Hunter	RE

Communiqués

07/08	Denali Therapeutics : Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q)	PU
06/08	Denali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights	GL
27/07	Denali Therapeutics to Report Second Quarter 2026 Financial Results and Business Highlights on August 6, 2026	GL
09/07	Denali Therapeutics to Give Opening Plenary Address at Alzheimer’s Association International Conference (AAIC) 2026 and Highlight Breakthroughs in Delivering Biologic Therapies Across Blood-Brain Barrier	GL
18/06	Denali Therapeutics Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million	GL
22/05	Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease	GL
08/05	Denali Therapeutics : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q)	PU
07/05	Denali Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights	GL
03/04	Denali Therapeutics Regains Full Rights to Investigational Therapy DNL593 (PTV:PGRN) for GRN-related Frontotemporal Dementia (FTD-GRN)	GL
25/03	Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH™ (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II)	GL
26/02	Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights	GL
05/02	Denali Therapeutics Presents Enzyme TransportVehicle™ Progress Across Three Clinical Programs for Treatment of Lysosomal Storage Disorders at 2026 WORLDSymposium™	GL
02/02	Denali Therapeutics To Host Webcast Highlighting Presentations on Enzyme TransportVehicle™ Programs at the 2026 WORLDSymposium™	GL
30/01	Denali Therapeutics Announces Data Presentations on Enzyme TransportVehicle Programs for Hunter Syndrome, Sanfilippo Syndrome Type A and Pompe Disease at Upcoming 2026 WORLDSymposium	AQ
29/01	Denali Therapeutics Announces Data Presentations on Enzyme TransportVehicle™ Programs for Hunter Syndrome, Sanfilippo Syndrome Type A and Pompe Disease at Upcoming 2026 WORLDSymposium™	GL
06/01	Denali Therapeutics Announces Key Anticipated Milestones and Priorities for 2026 Including Commercial Launch of Tividenofusp Alfa for Hunter Syndrome	GL
06/01	Denali Therapeutics Announces Key Anticipated Milestones and Priorities for 2026 Including Commercial Launch of Tividenofusp Alfa for Hunter Syndrome	AQ
30/12	The New England Journal of Medicine Publishes Phase 1/2 Study of Denali Therapeutics’ Tividenofusp Alfa (DNL310) for Hunter Syndrome (MPS II)	GL
10/12	Denali Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants	GL
09/12	Denali Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants	GL
04/12	Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement	GL
06/11	Denali Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights	GL
06/11	Denali Therapeutics Announces Board and Executive Leadership Updates	GL
13/10/25	Denali Therapeutics Announces FDA Review Extension of BLA for Tividenofusp Alfa for the Treatment of MPS II (Hunter Syndrome)	GL
11/08/25	Denali Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights	GL